Insulin receptor substrate I (IRSI) in glioma stem cells (GSCs) was determined to be a GLI1 transcriptional target; furthermore, GLI1 inhibition was found to antagonize IRSI-mediated MAPK pathway activation and obstruct IGF-I mediated cell survival in GSCs [210]. This evidence concerns the gene GLI1 and glioma.